Ketas® Treatment for Meniere's Disease

Abstract

We performed a randomized controlled study on the effect of Ibudilast (Ketas) in patients with Meniere's disease. Forty-six patients were included in the study: 28 were given 3 capsules of Ketas® daily (group A), and 18 were treated with other medications (group B). In group A, 20 of 28 patients (71%) were relieved of dizziness and 12 of 25 (48%) had reduction of tinnitus and 13 of 23 (57%) had improvement of hearing. In group B, 15 of 18 patients (83%) were relieved of dizziness and 7 of 15 (47%) had reduction of tinnitus and 4 of 18 (22%) had improvement of hearing. No side effects were noted in group A. The results suggest that Ketas® is a clinically useful drug for patients with Meniere's disease, especially in the treatment of hearing loss.